# Capricor Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Capricor Therapeutics, Inc). ## Overview Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell- and exosome-based therapies for Duchenne muscular dystrophy (DMD) and other high-unmet-need diseases. Its lead program is deramiocel, which the company is advancing through clinical development and regulatory review rather than through an established commercial product base. Capricor has built a partnering model around Nippon Shinyaku for U.S., Japan, and potential Europe commercialization, while retaining responsibility for development and manufacturing. The company currently has no approved products for sale, so its business is centered on clinical execution, regulatory milestones, and future revenue-sharing arrangements if approval is achieved. ## Products & services • Deramiocel for Duchenne muscular dystrophy (DMD) • Cell-based therapeutic development • Exosome-based therapeutic platform • Clinical trial development services for partnered programs • Manufacturing of clinical and potential commercial product • Regulatory and BLA submission support - **Lead therapeutic candidate** (70%) — Deramiocel, the company's lead cell therapy candidate being developed for DMD. - **Platform technologies** (10%) — Exosome-based and related regenerative medicine technologies that support pipeline expansion. - **Development collaborations** (20%) — Partner-funded clinical development, regulatory, and milestone-based collaboration revenue. - Deramiocel for Duchenne muscular dystrophy (DMD) - Cell-based therapeutic development - Exosome-based therapeutic platform - Clinical trial development services for partnered programs - Manufacturing of clinical and potential commercial product - Regulatory and BLA submission support ## Customers Capricor does not sell a broad portfolio of commercial medicines today; instead, its economic counterparties are primarily strategic partners and, eventually, patients and payers if deramiocel is approved. Nippon Shinyaku is the key commercial and distribution partner in the United States and Japan, and is intended to handle sales and distribution in those territories. In Europe, Capricor has a binding term sheet with Nippon Shinyaku that would assign sales and distribution responsibilities to the partner while Capricor retains development and manufacturing obligations. The ultimate end customers are DMD patients and the healthcare systems that would reimburse a rare-disease therapy, but near-term value creation depends on regulators and collaboration partners rather than direct product buyers. - **Strategic commercialization partners** (primary) — Nippon Shinyaku and related affiliates buy distribution rights and support commercialization because Capricor lacks a direct sales infrastructure. - **Regulatory authorities** (primary) — The FDA and non-U.S. regulators determine whether deramiocel can be marketed and therefore whether milestone and revenue-sharing economics can begin. - **DMD patients and clinicians** (primary) — Neuromuscular specialists and patients are the end users of deramiocel, driving clinical adoption if the therapy is approved. - **Payers and healthcare systems** (secondary) — Public and private reimbursement bodies would ultimately fund treatment access for a high-cost rare-disease therapy. - Nippon Shinyaku, which distributes deramiocel in the U.S. and Japan - NS Pharma, Inc., as the U.S. commercial affiliate under the distribution agreement - Potential European commercialization partner under the binding term sheet - Regulators such as the FDA, which determine approval timing and market access - DMD patients and treating neuromuscular specialists, the eventual therapy users - Payers and health systems that would reimburse a rare-disease biologic ## Geography Capricor is headquartered in the United States and its core development, regulatory, and manufacturing activities are centered there. The United States is the most important market because the company has already submitted a BLA to the FDA and has a U.S. distribution agreement with Nippon Shinyaku. Japan is another key market through a separate commercialization and distribution agreement, and Europe is a potential third region under a binding term sheet. Because the company is still pre-commercial, geography matters less as a source of current revenue than as a map of regulatory approvals, partner obligations, and future market access. - **United States** (100%) — Current disclosed commercial agreement and regulatory focus are primarily U.S.-based; no revenue geography table was provided. - United States is the core operating base and primary regulatory market - FDA review is central because the BLA was submitted for deramiocel in the U.S. - Japan is covered by a separate commercialization and distribution agreement - Europe is a potential expansion market under a binding term sheet - Development and manufacturing responsibilities remain largely with Capricor - Commercial distribution is intended to be handled by Nippon Shinyaku partners ## Strategy Capricor's strategy is to convert deramiocel from a clinical-stage asset into an approved rare-disease therapy, starting with DMD in the United States. The company is using a partner-led commercialization model so it can focus on clinical development, manufacturing, and regulatory execution while Nippon Shinyaku handles distribution. A second strategic priority is to extend the same asset into Japan and potentially Europe through regional agreements that can generate upfront, milestone, and revenue-share economics. The company is also investing in its exosome platform and manufacturing capabilities to support future pipeline breadth and reduce dependence on a single program. - **Secure U.S. regulatory approval for deramiocel** (short-term) — Approval is the main gate to first commercial revenue and to the large milestone payments tied to the U.S. distribution agreement. - **Finalize and expand regional partnering** (medium-term) — Partnering reduces commercial build-out risk and allows Capricor to monetize ex-U.S. markets without a direct sales infrastructure. - **Strengthen manufacturing and clinical execution** (short-term) — The company must reliably supply product for trials and eventual commercial use to avoid delays that could jeopardize approval and launch. - **Broaden the pipeline through exosome-based research** (long-term) — A second platform could reduce single-asset dependence and create longer-term optionality beyond DMD. - Advance deramiocel through late-stage development and regulatory approval - Use Nippon Shinyaku to commercialize rather than building a full sales force - Capture upfront, milestone, and revenue-share economics from partnerships - Expand deramiocel into Japan and Europe through regional agreements - Maintain manufacturing control to support clinical and potential commercial supply - Develop exosome-based programs to broaden the pipeline beyond DMD ## Risks Capricor's business is highly dependent on clinical trial success, regulatory approval, and the ability to manufacture product consistently, so any setback can materially delay or eliminate future revenue. The company also faces concentration risk because deramiocel is the main value driver and the commercial model depends on Nippon Shinyaku as a key partner. As a clinical-stage biotech, it is exposed to typical industry risks such as trial failures, safety findings, FDA review risk, intellectual property disputes, and the need for repeated capital raises before meaningful product revenue begins. The recent securities class action and derivative claims add legal cost, management distraction, and potential stock-price volatility. International expansion adds further regulatory and execution risk because approval and commercialization timelines can differ across the U.S., Japan, and Europe. - **Clinical development failure for deramiocel** [critical] — The company has no approved products, so its future revenue depends heavily on successful trial outcomes and a positive benefit-risk profile. - **Regulatory approval risk** [high] — The BLA and any future ex-U.S. approvals are prerequisites for commercialization and milestone payments. - **Manufacturing and supply risk** [high] — Capricor is responsible for manufacturing deramiocel for clinical and potential commercial use, and any quality or capacity issue could delay supply. - **Partner concentration risk** [high] — Nippon Shinyaku is central to U.S., Japan, and potential Europe commercialization, so partner decisions materially affect market access. - **Litigation and stockholder claims** [medium] — The company disclosed a putative class action and derivative action, which can create legal expense and management distraction. - Clinical trial failure or unfavorable data could stop deramiocel development - FDA or other regulatory delays could postpone approval and milestone receipts - Manufacturing or supply-chain problems could disrupt trials or launch readiness - Dependence on Nippon Shinyaku concentrates commercial and execution risk - Legal claims from stockholders can increase costs and distract management - Need for external financing remains high until product revenue is established - Rare-disease pricing, reimbursement, and market adoption may be uncertain ## Accounting Capricor's accounting is dominated by judgment-heavy areas typical of a clinical-stage biotech. Clinical trial accruals are estimated using patient progression, vendor reporting, and management assumptions, so expense recognition can move materially between quarters as trial activity changes. Revenue recognition is also nuanced because upfront collaboration payments and milestone receipts may be recorded as deferred revenue and recognized over time based on performance obligations, which can create uneven quarterly revenue. The company also has to estimate stock-based compensation, research and development costs, and any contingent obligations tied to collaboration or financing arrangements. Because there are no approved products yet, reported results can be highly sensitive to timing differences in development spending, milestone achievement, and deferred revenue release. - **Clinical trial accruals** — Can materially affect reported operating loss and comparability across quarters - **Deferred revenue and collaboration accounting** — Can shift revenue between periods and create non-cash revenue timing effects - **Stock-based compensation** — Raises reported R&D and G&A expense without immediate cash outflow - **Contingent milestone accounting** — Can cause significant quarter-to-quarter volatility in revenue - Clinical trial accruals depend on estimates of patient progress and vendor services - Upfront collaboration payments may be deferred and recognized over time - Milestone payments can create lumpy revenue recognition when regulatory events occur - R&D expense timing can shift with trial pace, manufacturing activity, and vendor invoices - Stock-based compensation is a meaningful non-cash expense for a development-stage biotech - Deferred revenue estimates depend on management's view of future performance obligations --- *Last updated: 2026-09-24T10:46:57.257654+00:00*